Literature DB >> 6866592

Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid.

Y P Chan, J M Swanson, S S Soldin, J J Thiessen, S M Macleod, W Logan.   

Abstract

Methylphenidate HCl (Ritalin) is often prescribed for the treatment of hyperactivity and is usually administered orally 30 minutes to 1 hour before meals, based on an assumption that meals may interfere with the absorption or metabolism of the drug. Seven boys who were taking methylphenidate regularly for the treatment of hyperactivity were hospitalized and given their established dose of the drug intravenously or orally, either with breakfast or in a fasted state. Blood samples were taken to determine the pharmacokinetics of the drug in each condition. Few differences between the "fed" and "fasted" states were noted, but the statistically significant differences indicated that meals accelerate rather than impede the absorption of methylphenidate.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6866592

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  27 in total

Review 1.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 2.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

Review 3.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 4.  A review of psychostimulant-induced neuroadaptation in developing animals.

Authors:  Normand Carrey; Michael Wilkinson
Journal:  Neurosci Bull       Date:  2011-06       Impact factor: 5.203

5.  Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Authors:  Kennerly S Patrick; Wendy Rodriguez
Journal:  Drug Metab Dispos       Date:  2019-04-26       Impact factor: 3.922

6.  Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery.

Authors:  Guinevere H Bell; William C Griffin; Kennerly S Patrick
Journal:  Pharmacol Biochem Behav       Date:  2011-09-08       Impact factor: 3.533

Review 7.  Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.

Authors:  Vanessa R Anderson; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

8.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Methylphenidate and cognitive therapy: a comparison of treatment approaches with hyperactive boys.

Authors:  R T Brown; M E Wynne; R Medenis
Journal:  J Abnorm Child Psychol       Date:  1985-03

10.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.